SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.

By C. Bruns, I. Lewis, U. Briner, G. Meno-Tetang, G. Weckbecker. European Journal of Endocrinology, 2002

704 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology

View Paper: https://www.semanticscholar.org/paper/d0cb168e0c9d213c75351a7184ae775f21903e03

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. M. H. Murad

Citations in the corpus

• Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. (2015, background): “Pasireotide Pasireotide is a somatostatin receptor (SST) agonist that binds to four of the five SST subtypes with substantially higher affinity for SST1 and SST5 than octreotide or lanreotide (153, 154).”